On May 26, 2026 Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, reported progress on its prospective observational case-control study designed to train and validate a blood test for multi-cancer early detection (MCED) at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting from May 29-June 2, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CAMPERR study (NCT05366881) is enrolling 6,300 participants at 15 sites with nationwide representation across the US. Approximately 98% of participants have been enrolled to date, and enrollment is expected to be complete by the end of 2026.

"CAMPERR is one of the most comprehensive prospective observational MCED studies conducted to date," said Anne-Renee Hartman, MD, Co-Founder and Chief Medical Officer at Adela. "The study’s scale, demographic diversity, and scientific rigor provide high confidence that a lab developed test (LDT) for MCED trained and validated with CAMPERR samples will be highly generalizable, performing reliably across a broad and diverse population."

CAMPERR is enrolling 2,400 participants with newly diagnosed, untreated cancer or cancer recurrence across 20 pre-selected cancer types, with blood collected prior to treatment initiation. Together, these 20 cancer types represent 93% of annual cancer incidence and 88% of annual cancer deaths in the United States. An additional 3,900 cancer-free control participants have been enrolled. A subset of participants with Stage I–III lung cancer will undergo additional blood draws and longitudinal follow-up, enabling training and validation of a test for MRD-based recurrence detection.

Adela’s genome-wide methylome enrichment platform is unique from other methylation-based MCED tests because it utilizes a high-affinity enrichment process, enabling capture and preservation of more genomic material for sequencing compared to other platforms that use enzymatic or chemical treatment (bisulfite conversion).

"The methylome carries one of the richest cancer signals in the blood, particularly for detecting early-stage disease and identifying cancer signal of origin," said Daniel De Carvalho, PhD, Co-Founder and Chief Scientific Officer at Adela. "Adela’s genome-wide methylome enrichment platform is designed to capture that signal while preserving the integrity of cfDNA, rather than relying on chemical conversion methods that can degrade limited blood-derived DNA. This allows us to access a broad, biologically informative view of cancer-associated methylation from a blood draw, with the potential to improve sensitivity, in particular for early stage and low-shedding cancers, when tumor-derived DNA is present at very low levels in the blood."

At the ASCO (Free ASCO Whitepaper) Annual Meeting, Adela is also presenting data using an updated classifier for recurrence detection for head & neck squamous cell carcinoma. Adela previously reported clinical validation results for head & neck cancer in Annals of Oncology.

Adela’s test for MRD is currently available to select providers and institutions for use to monitor for recurrence in head & neck cancer. Adela plans to expand commercialization of the test later this year for use in patients with solid tumors treated with immunotherapy to monitor response and help guide treatment decision-making. The test is also broadly available for use by biopharmaceutical companies and other investigators for recurrence monitoring and immunotherapy response monitoring, including for biomarker discovery and drug development.

Presentation Details

Abstract 6084: Evaluation of a tissue-free genome-wide methylome enrichment assay for detecting molecular residual disease (MRD) in patients with head and neck squamous cell carcinoma (HNSCC).

Dr. Geoffrey Liu1

Hall A, Poster Board: 541

Saturday, May 30, 2026: 1:30 PM-4:30 PM CDT

Abstract TPS10628: CAMPERR: A multicenter, prospective, observational study to evaluate a cfDNA-based genome-wide methylation enrichment assay for multicancer early detection (MCED), identification of molecular residual disease, and relapse prognostication.

Dr. Gregory Idos2

Hall A, Poster Board: 589a

Monday, June 1, 2026: 1:30 PM-4:30 PM CDT

(Press release, Adela, MAY 26, 2026, View Source [SID1234666066])

On May 26, 2026 Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies, "Sun Pharma") reported the company will share updated results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) expansion cohort from the pivotal CK-301-101 trial of UNLOXCYT (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting on May 31, 2026 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the investigator-reviewed data being presented at ASCO (Free ASCO Whitepaper), 64 patients with laCSCC received ≥1 dose of UNLOXCYT. The median age of patients in the cohort was 77 years old and 66% were male. This reflects the population commonly seen in clinical practice. Patients received a median of 29 doses over a median treatment duration of 60 weeks. The objective response rate was 50%, including 17 (27%) complete responses and 15 (23%) partial responses. Over a median follow-up of 31 months, responses were durable and the median duration of response was not yet reached.

"These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC, which is associated with long-term clinical outcomes. The durability of these responses, a primary therapeutic objective, was achieved alongside a manageable safety profile," said Rahul Ladwa, MBChB, BSc, FRACP, MPhil, Medical Oncologist at the Princess Alexandra Hospital and Greenslopes Private Hospital; Associate Professor, The University of Queensland, Australia; and presenting study co-author at ASCO (Free ASCO Whitepaper).

The safety profile was comparable to what was observed in an earlier analysis of a smaller cohort.

The most common adverse events (AEs) were anemia and diarrhea, recorded in 17 (27%) patients each.
Immune-related adverse reactions (irAEs) were observed in 22 (34%) patients.
Grade ≥3 irAEs occurred in 1 (2%) patient and were dermatologic in nature (maculo-papular and pruritic rashes) and considered treatment-related.
Treatment-emergent AEs (TEAEs) were reported in 61 (95%) patients and considered treatment-related in 50 (78%) patients; none were fatal.
Grade ≥3 TEAEs were reported in 26 (41%) patients and considered treatment-related in 7 (11%).
"The findings from this large cohort of patients are impressive from both an efficacy and tolerability perspective. Patients with laCSCC are older and have many comorbidities, so we need treatment options that are both efficacious and well tolerated, so patients remain on therapy and experience meaningful benefit," said Emily Ruiz, MD, MPH, Associate Professor of Dermatology, Harvard Medical School, Academic Director of the Micrographic Surgery Center at Brigham and Women’s Hospital; co-founder of Skin Cancer Champions; and study co-author. "Cosibelimab seems to work differently than other checkpoint inhibitors by restoring the adaptive immune response and engaging the innate immune system while preserving the PD-1/PD-L2 pathway. We believe this may explain the results we observe in these patients."

Poster Presentation Details

Title: Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study
Poster Session: Melanoma/Skin Cancers
Abstract Number: 9585
Poster Board Number: 301
Date and Time: May 31, 2026; 9:00am-12:00pm CDT
Presenter: Dr. Rahul Ladwa
"We’re looking forward to presenting these data at ASCO (Free ASCO Whitepaper)’s Annual Meeting later this month, highlighting pivotal results from the second largest ever reported prospective study of laCSCC patients treated with PD-(L)1 monotherapy, reinforcing our commitment to the skin cancer community," said Ahmad Naim, MD, Senior Vice President, North America Chief Medical Officer, Sun Pharma. "With a median duration of response not yet reached after more than two and a half years of follow-up, UNLOXCYT continues to demonstrate the kind of clinically meaningful efficacy with durable clinical responses and well-tolerated treatment option that patients with laCSCC need."

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks.

UNLOXCYT (cosibelimab-ipdl) was approved at 1,200 mg Q3W because PK/PD modeling showed it provides similar overall exposure and PD-L1 receptor coverage as the trial regimen of 800 mg Q2W. Since checkpoint inhibitors have flat exposure-response curves, they have been utilized with more convenient dosing schedules if equivalent efficacy and safety are maintained. The safety analyses included patients who received both 800 mg Q2W and 1,200 mg Q3W.

About Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (CSCC) is among the most common skin cancers worldwide. While early stages are treatable, an estimated 40,000 US patients each year progress to advanced disease, resulting in nearly 15,000 deaths.

Important risk factors for CSCC include chronic ultraviolet radiation exposure and immunosuppressive conditions. In addition to being life threatening, CSCC causes significant functional morbidities and cosmetic deformities due to tumors that commonly arise in the head and neck region and that invade blood vessels, nerves, and vital organs such as the eye or ear.

(Press release, Sun Pharma, MAY 26, 2026, https://www.prnewswire.com/news-releases/at-the-asco-2026-annual-meeting-sun-pharma-to-present-pivotal-long-term-follow-up-data-on-unloxcyt-cosibelimab-ipdl-302781880.html [SID1234666065])

On May 26, 2026 Mercy BioAnalytics, Inc., a pioneer in blood-based early cancer detection, reported that it will present two abstracts at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting highlighting results from studies using biospecimens from the National Lung Screening Trial (NLST) repository.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NLST was an NCI-sponsored randomized controlled trial that demonstrated a significant mortality benefit associated with annual low-dose CT-based screening. NLST established a biospecimen repository for the purpose of enabling the validation of early detection lung cancer biomarkers that might augment or replace low-dose CT (LDCT).1 To date, nearly 900 requests for NLST data or biospecimens have been approved.2 To our knowledge, Mercy’s ASCO (Free ASCO Whitepaper) presentation will be the first use of blood specimens from NLST subjects for preliminary validation of early detection lung cancer biomarkers. This work represents an important milestone in advancing blood-based approaches for lung cancer screening and lung nodule triage in elevated-risk subjects.

The first study reports results from a blinded evaluation of a novel blood-based lung cancer screening assay in elevated-risk subjects from the NLST. In this dataset, the blood-based screening assay showed similar sensitivity to low-dose CT across two annual screening encounters and detected lung cancers that were missed by low-dose CT, supporting further evaluation of the assay for lung cancer screening in the elevated-risk population.

The second study reports results from a blinded evaluation of a novel blood-based pulmonary nodule triage assay in elevated-risk subjects from the NLST. Six percent of LDCT-screened subjects in NLST were scored as 3 or 4A using the Lung-RADS framework. Despite a 4% prevalence of cancer in this population, immediate diagnostic workup is not recommended. Mercy’s blood-based assay exhibited 43% sensitivity for the detection of lung cancer in these subjects, supporting further evaluation as a reflex approach for LDCT-detected pulmonary nodules.

"The results of the National Lung Screening Trial documenting a 20% decrease in lung cancer mortality with low-dose CT has led to practice changing recommendations with screening now recommended in high-risk groups. Mercy’s encouraging preliminary results are exactly why the NCI set up the NLST biospecimen repository: to enable validation of promising blood biomarkers. A blood test like Mercy’s could increase lung cancer screening uptake and make evaluation of pulmonary nodules more precise, potentially leading to more lives saved," said Dr. Christine Berg, M.D. the now retired NCI lead investigator on the NLST. "I am excited about these results. I have the good fortune to serve on the Clinical Advisory Board at Mercy and observed the meticulous care with which this work was done."

These results support further evaluation which is now underway of Mercy’s blood-based approaches to lung cancer screening and risk stratification of LDCT-detected pulmonary nodules.

Mercy is continuing to advance blood-based approaches designed to expand access to earlier detection and improve decision-making in lung cancer screening and follow-up.

Presentation details for the two accepted abstracts will be available through the ASCO (Free ASCO Whitepaper) Annual Meeting program and Mercy’s communications channels as the meeting approaches.

(Press release, Mercy BioAnalytics, MAY 26, 2026, View Source [SID1234666064])

On May 26, 2026 Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University—and Hackensack University Medical Center reported research findings at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The meeting is the premier event for cancer professionals and takes place in Chicago from May 29 to June 2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The future of cancer treatment begins with translating today’s pioneering exploration into tomorrow’s standard of care, a theme that resonates strongly at this year’s ASCO (Free ASCO Whitepaper) meeting. For patients who do not respond to standard treatments, it is critical that they have access to a world-class research program. At the John Theurer Cancer Center, our globally recognized investigators are committed to this translation, driving the latest advances in cellular therapy, immunotherapy, and other innovative areas to improve outcomes for patients across the Hackensack Meridian Health network and beyond," said Dr. Andre Goy, chair, vice president, physician-in-chief of oncology, at Hackensack Meridian John Theurer Cancer Center.

Many of the studies focus on innovative therapies for blood cancers and novel immunotherapies. These are areas of expertise for John Theurer Cancer Center, New Jersey’s largest cancer center. The findings of these investigations have the potential to change the treatment and understanding of hematologic, solid tumors, melanoma and other cancers.

ASCO posters/presentations/publications that include authors from John Theurer Cancer Center:

Solid Tumors

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.
Hypercalcemia as a marker of in-hospital mortality and resource utilization in breast cancer: A national analysis.
Baseline biomarker analysis and clinical outcomes of the PD-1/TGFβR2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC).
Phase 1 study of LB1908, an autologous claudin 18.2-targeted CAR-T cell product, in subjects with advanced gastroesophageal adenocarcinoma.
Phase I, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug conjugate (ADC) in patients with advanced solid tumors.
BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.
A phase 1, first-in-human, multicenter study of ZW251, a novel glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in participants with hepatocellular carcinoma (HCC).
Real-world outcomes of amivantamab monotherapy in advanced EGFR-mutant non-small cell lung cancer.
Real-world efficacy and safety of tarlatamab in small cell lung cancer (SCLC) and extrapulmonary small cell carcinoma (EPSCC): A single-center experience.
Phase Ib results from the phase Ib/II study of [177Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer.
Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).
Hematologic Malignancies

Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.
Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.
Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.
KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): First real-world data from the CIBMTR.
Carfilzomib-based combinations for Waldenström macroglobulinemia: Real-world experience from a single center.
MACROD2 and CDKN2A in multiple myeloma: Insights to germline susceptibility and cytogenetic risk from long-read Nanopore sequencing.
Real-world outcomes and subsequent treatment utilization following anti-B-cell maturation antigen antibody-drug conjugate exposure in patients with multiple myeloma.
Immunotherapy

ASP2998, a trophoblast cell-surface antigen 2 (TROP2)–targeted immunostimulatory antibody-drug conjugate with dual payloads, in patients with locally advanced unresectable or metastatic solid tumors: A phase 1b/2 study.
A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors.
Melanoma

Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
Models of Care

Are socio-economic status indicators barriers for enrollment in phase 1 clinical trials?
Enrollment outcomes after screening in phase 1 oncology clinical trials: Real-world evidence from a NCI-designated cancer center.
Rethinking risk: Disparities and genetic testing outcomes from a novel public-facing cancer prevention program.
Risk stratification in systemic AL amyloidosis with cardiac involvement using a multiparametric echocardiography score.

(Press release, John Theurer Cancer Center, MAY 26, 2026, View Source [SID1234666063])

On May 26, 2026 GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, reported that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live and replay webcasts may be accessed in the investor relations section of GRAIL’s website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

(Press release, Grail, MAY 26, 2026, View Source [SID1234666062])